SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (213)12/16/1997 7:46:00 AM
From: biao luo  Read Replies (1) of 4474
 
I remember a seminar by Stuart Schreiber in which he presented a derivative of Fk506. This derivative does not bind wild type FKBP. Then they either designed or screened to find a mutant FKBP that binds their FK506 derivative. FK506 in itself is a potent immunosuppresant working through endogenous FKBP, this strategy eliminates this effect. Just wondering if Ariad is using the same strategy.
I also read an article pubs.acs.org
mentioning that Ariad was doing combinatorial chemstry based on Schreiber's work. Do people know what happened to it?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News